Biotricity Inc BTCY has a multi-billion dollar target addressable market, which should expand as an ecosystem is created for solutions to chronic conditions, according to Maxim Group.
The Biotricity Analyst: Allen Klee initiated coverage of Biotricity with a Buy rating and a price target of $6.
The Biotricity Thesis: The company has been generating triple-digit year-over-year revenue growth and could continue doing so through fiscal 2024, Klee said in the initiation note.
Biotricity’s first product, Bioflux, is a “best-in-class offering in terms of data quality, built-in connectivity, and upgraded software to improve automation and results,” the analyst noted.
He added that the company plans to launch a new product every 12 to 18 months, in order to expand the ecosystem for cardiologists.
“In June, Bioheart will go live with a direct-to-consumer, best-in-class heart monitoring product” and its next product with the FDA is Biotres, focused on monitoring less risky patients, Klee wrote.
He estimates the total addressable market at $1 billion for Bioflux and at $2 billion for Biotres.
“We project annual revenue growth of over 100% through FY24, and gross margin to improve from close to 50% today, to 75%+ when at scale,” the analyst said.
BTCY Price Action: Shares were down 6.25% to $2.45 on Thursday morning.
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.